Bumsoo Park

Bumsoo Park

Auto-generated profile, based on publicly available information

Bumsoo Park

University of Michigan Medical School

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2012 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
YCYuni Choi
Yuni Choi
BPBumsoo Park
Bumsoo Park
BJByong Chang Jeong
Byong Chang Jeong
SSSeong Il Seo
Seong Il Seo
SJSeong Soo Jeon
Seong Soo Jeon
HLHyun Moo Lee
Hyun Moo Lee
Growing evidence suggests that obesity, an established cause of renal cell cancer (RCC), may also be associated with a better prognosis. To evaluate the association between RCC survival and obesity, we analyzed a large cohort of patients with RCC and undertook a meta‐analysis of the published evidence. We collected clinical and pathologic data from 1,543 patients who underwent nephrectomy for RCC between 1994 and 2008 with complete follow‐up through 2008. Patients were grouped according to BMI (kg/m2): underweight <18.5, normal weight 18.5 to <23, overweight 23 to <25 and obese ≥25. We estimated survival using the Kaplan–Meier method and Cox proportional hazard models to examine the impact of BMI on overall survival (OS) and cancer‐specific survival (CSS) with adjustment for covariates. We performed a meta‐analysis of BMI and OS, CSS and recurrence‐free survival (RFS) from all relevant studies using a random‐effects model. The 5‐year CSS increased from 76.1% in the lowest to 92.7% in the highest BMI category. A multivariate analysis showed higher OS [hazard ratio (HR) = 0.45; 95% CI: 0.29–0.68) and CSS (HR = 0.47; 95% CI: 0.29–0.77] in obese patients than in normal weight patients. The meta‐analysis further corroborated that high BMI significantly improved OS (HR = 0.57; 95% CI: 0.43–0.76), CSS (HR = 0.59; 95% CI: 0.48–0.74) and RFS (HR = 0.49; 95% CI: 0.30–0.81). Our study shows that preoperative BMI is an independent prognostic indicator for survival among patients with RCC.

1 July 2013 in Journal of Endourology
Verified
Journal Article
Closed access
KCKyung Jin Chung
Kyung Jin Chung
BPBong Hee Park
Bong Hee Park
BPBumsoo Park
Bumsoo Park
JLJun Ho Lee
Jun Ho Lee
WKWoo Jung Kim
Woo Jung Kim
DHDeok Hyun Han
Deok Hyun Han
Background and Purpose: Malignant ureteral obstruction (MUO) is a common condition and an intractable situation for patients with advanced cancer. There is currently no ideal ureteral stent to release the obstruction. Our purpose was to evaluate the clinical efficacy and safety of a novel, double-layered, coated, self-expandable metallic mesh stent (Uventa ™ ) in MUO. Patients and Methods: In a retrospective design, a total of 71 ureter units (54 patients) were included from December 2009 to March 2012. Indications were those who had MUO with a polymeric Double-J stent malfunction, severe polymeric stent irritation, or severe pain during periodic stent change. Patients underwent Uventa placement using a retrograde approach. Results: All stents were positioned at the proper site without procedure-related complications. The overall success (no obstruction and no additional intervention except supplementary Uventa placement) and primary success (no obstruction and no additional intervention) rates were 81.7% (58/71 ureter units) and 64.8% (46/71 ureter units) during the follow-up period, which had a median of 308 (35–802) days. The most common reason for primary failure was tumor progression beyond the stent segment (75.0%), followed by reactive hyperplasia at the stent tips (12.5%), bladder invasion of the primary tumor (8.0%), and stent-related pain (8.0%). Twelve patients had overall success after secondary Uventa placement. There were no severe complications. The complications included persistent flank pain (15.5%), lower urinary tract symptoms (7.0%), acute pyelonephritis (2.8%), stent migration (2.8%), and persistent hematuria (2.8%). Conclusions: These data show that Uventa can be an effective and safe option for palliative treatment of patients with MUO in a large series of patients.

6 February 2013 in Cancer Science
Verified
Journal Article
Open access
PDF file
BPBumsoo Park
Bumsoo Park
BJByong Chang Jeong
Byong Chang Jeong
YCYoon‐La Choi
Yoon‐La Choi
GKGhee Young Kwon
Ghee Young Kwon
JLJoung Eun Lim
Joung Eun Lim
KLKyu‐Sung Lee
Kyu‐Sung Lee
Most of the cancer xenograft models are derived from tumor cell lines, but they do not sufficiently represent clinical cancer characteristics. Our objective was to develop xenograft models of bladder cancer derived from human tumor tissue and characterize them molecularly as well as histologically. A total of 65 bladder cancer tissues were transplanted to immunodeficient mice. Passagable six cases with clinico‐pathologically heterogeneous bladder cancer were selected and their tumor tissues were collected (012T, 025T, 033T, 043T, 048T, and 052T). Xenografts were removed and processed for the following analyses: (i) histologic examination, (ii) short tandem repeat (STR) genotyping, (iii) mutational analysis, and (iv) array‐based comparative genomic hybridization (array‐CGH). The original tumor tissues (P 0) and xenografts of passage 2 or higher (≥P2) were analyzed and compared. As a result, hematoxylin and eosin staining revealed the same histologic architecture and degree of differentiation in the primary and xenograft tumors in all six cases. Xenograft models 043T_P2 and 048T_P2 had completely identical STR profiles to the original samples for all STR loci. The other models had nearly identical STR profiles. On mutational analysis, four out of six xenografts had mutations identical to the original samples for TP53, HRAS, BRAF, and CTNNB1. Array‐CGH analysis revealed that all six xenograft models had genomic alterations similar to the original tumor samples. In conclusion, our xenograft bladder cancer model derived from patient tumor tissue is expected to be useful for studying the heterogeneity of the tumor populations in bladder cancer and for evaluating new treatments.

27 July 2012 in Scandinavian Journal of Urology
Verified
Journal Article
Closed access
PDF file
BPBumsoo Park
Bumsoo Park
WKWoojung Kim
Woojung Kim
BJByong Chang Jeong
Byong Chang Jeong
SJSeong Soo Jeon
Seong Soo Jeon
HLHyun Moo Lee
Hyun Moo Lee
SSSeong Il Seo
Seong Il Seo
Objective. The aim of this study was to compare oncological and functional outcomes of pure laparoscopic radical prostatectomy (LRP) and robotic-assisted laparoscopic radical prostatectomy (RALRP) performed by a single surgeon. Material and methods. In total, 327 consecutive patients with prostate cancer who underwent radical prostatectomy (144 with LRP and 183 with RALRP) were enrolled. No significant differences were found in prostate-specific antigen level, biopsy Gleason score, clinical T stage or D'Amico risk stratification between the two groups. The operating time was longer in the LRP group (p < 0.001). The RALRP group patients had significantly lower postoperative pain numerical rating scale (NRS) (p = 0.016) and catheter duration (p < 0.001). There were no differences in pathological Gleason score, pathological T stage or positive surgical margin rate. No differences were found in biochemical recurrence-free survival. Postoperative pad-free continence rates revealed a more rapid recovery in the RALRP group, but rates at 12 months were not significantly different. Multivariate analysis showed that the type of surgery was a strong independent factor to predict early postoperative pad use. Postoperative potency rates were not significantly different at 3, 6 and 12 months in patients who underwent nerve-sparing procedures. Conclusions. LRP and RALRP performed by a single surgeon yielded similar results in terms of safety and oncological outcomes. More favorable outcomes were noted in operating time, pain NRS and catheter duration, as well as urinary continence recovery time. Therefore, RALRP showed more favorable components in terms of postoperative quality of life than LRP.

1 January 2013 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
BPBumsoo Park
Bumsoo Park
BJByong Chang Jeong
Byong Chang Jeong
SSSeong Il Seo
Seong Il Seo
SJSeong Soo Jeon
Seong Soo Jeon
HCHan Yong Choi
Han Yong Choi
HLHyun Moo Lee
Hyun Moo Lee
Park B, et al. J Korean Med Sci. 2013 Feb;28(2):227-236. http://dx.doi.org/10.3346/jkms.2013.28.2.227

19 November 2013 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
KLK.-S. Lee
K.-S. Lee
BPB. Park
B. Park
JKJ. H. Kim
J. H. Kim
HKH. G. Kim
H. G. Kim
JSJ. T. Seo
J. T. Seo
MCMyung-Soo Choo
Myung-Soo Choo
Aims Our objective was to compare the efficacy and safety of imidafenacin over fesoterodine in patients with overactive bladder (OAB). Methods This study is a randomised, double‐blind, parallel‐group, fesoterodine‐controlled study in patients with continuous OAB symptoms for ≥ 3 months, daily mean voiding frequency (DMVF) ≥ 8, and daily mean urgency or urgency incontinence frequency ≥ 2. A twice‐daily 0.1 mg imidafenacin with placebo, or once‐daily 4 mg fesoterodine with placebo were administered for 12 weeks. The primary efficacy end‐point was the difference in DMVF at 12 weeks. The secondary efficacy end‐points were differences in daily mean: (i) voiding frequency at 4 and 8 weeks; (ii) urgency frequency; (iii) urgency incontinence frequency; (iv) incontinence frequency; (v) nocturia frequency; and (vi) quality of life score. The variables for safety analysis were adverse events, vital signs, residual urine volume and clinical laboratory tests. An efficacy analysis was conducted in per‐protocol patients and the safety analysis was conducted in all randomised patients. Results The differences in DMVF at 12 weeks were −3.38 ± 3.63 and −2.45 ± 3.73 in the imidafenacin and fesoterodine groups, respectively, and the difference was not significant between the two groups. Imidafenacin was non‐inferior to fesoterodine, and the lower limit of 95% two‐sided confidence intervals was −0.53. The other six secondary end‐points and variables for safety analysis showed no difference between the two groups. Conclusions Imidafenacin was non‐inferior to fesoterodine in terms of efficacy, and showed no significant difference in terms of safety.